Last reviewed · How we verify
becaplermin gel
Becaplermin gel, marketed by Assistance Publique - Hôpitaux de Paris, is a topical treatment with a key composition patent expiring in 2028. The drug's primary strength lies in its established market presence and regulatory approval. The primary risk is the potential increase in competition following the 2028 patent expiry.
At a glance
| Generic name | becaplermin gel |
|---|---|
| Sponsor | Assistance Publique - Hôpitaux de Paris |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Study of Combined Topical Growth Factor and Protease Inhibitor in Chronic Wound Healing (PHASE3)
- Endogenous Progenitors Cell Therapy for Diabetic Foot Ulcers (PHASE1)
- Comparative Study of 3 Dose Regimens of BioChaperone to Becaplermin Gel for the Treatment of Diabetic Foot Ulcer (PHASE1, PHASE2)
- Becaplermin Gel for MARTORELL's Hypertensive Leg Ulcers (PHASE3)
- Efficacy of R-Pdf/Gbb in Healing Wounds Caused by Third Degree Thermal and Electrical Burns (PHASE2)
- A Study on the Efficacy and Safety of Long-Term Treatment and Re-Treatment of Lower Extremity Diabetic Ulcers With REGRANEX (PHASE3)
- Evaluation of the Safety Follow-up of Becaplermin or Placebo Gel Following Treatment of Chronic, Full Thickness Diabetic Ulcers
- Evaluation of Windowed Casts With and Without Regranex® Gel for Healing Diabetic Neuropathic Ulcers (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- becaplermin gel CI brief — competitive landscape report
- becaplermin gel updates RSS · CI watch RSS
- Assistance Publique - Hôpitaux de Paris portfolio CI